KYTX stock icon

Kyverna Therapeutics

4.89 USD
+0.11
2.30%
At close Nov 1, 4:00 PM EDT
After hours
4.89
+0.00
0.00%
1 day
2.30%
5 days
-5.23%
1 month
3.38%
3 months
-37.71%
6 months
-70.56%
Year to date
-83.70%
1 year
-83.70%
5 years
-83.70%
 

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 112

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

175% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 12

2.67% more ownership

Funds ownership: 71.69% [Q1] → 74.36% (+2.67%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

3% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 30

1% less funds holding

Funds holding: 89 [Q1] → 88 (-1) [Q2]

53% less call options, than puts

Call options by funds: $48K | Put options by funds: $102K

69% less capital invested

Capital invested by funds: $767M [Q1] → $241M (-$527M) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
43%
upside
Avg. target
$9
84%
upside
High target
$13
166%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
UBS
Trung Huynh
60% 1-year accuracy
3 / 5 met price target
166%upside
$13
Buy
Initiated
10 Oct 2024
HC Wainwright & Co.
Mitchell Kapoor
50% 1-year accuracy
66 / 131 met price target
43%upside
$7
Neutral
Reiterated
19 Sept 2024
HC Wainwright & Co.
Mitchell Kapoor
50% 1-year accuracy
66 / 131 met price target
43%upside
$7
Neutral
Maintained
15 Aug 2024

Financial journalist opinion

Charts implemented using Lightweight Charts™